Compare Biocon Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SANOFI INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SANOFI INDIA BIOCON /
SANOFI INDIA
 
P/E (TTM) x 25.1 41.3 60.9% View Chart
P/BV x 3.3 7.2 46.0% View Chart
Dividend Yield % 0.3 1.2 28.9%  

Financials

 BIOCON    SANOFI INDIA
EQUITY SHARE DATA
    BIOCON
Mar-18
SANOFI INDIA
Dec-18
BIOCON /
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1886,840 17.4%   
Low Rs3054,630 6.6%   
Sales per share (Unadj.) Rs68.71,203.1 5.7%  
Earnings per share (Unadj.) Rs7.6165.3 4.6%  
Cash flow per share (Unadj.) Rs14.0209.9 6.7%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.11.5 9.1%  
Book value per share (Unadj.) Rs86.3963.6 9.0%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.8 227.9%   
Avg P/E ratio x98.934.7 284.9%  
P/CF ratio (eoy) x53.427.3 195.5%  
Price / Book Value ratio x8.66.0 145.3%  
Dividend payout %13.250.8 26.1%   
Avg Mkt Cap Rs m447,900132,078 339.1%   
No. of employees `0006.13.3 186.3%   
Total wages/salary Rs m9,3114,068 228.9%   
Avg. sales/employee Rs Th6,705.88,393.8 79.9%   
Avg. wages/employee Rs Th1,514.21,232.4 122.9%   
Avg. net profit/employee Rs Th736.91,153.0 63.9%   
INCOME DATA
Net Sales Rs m41,23427,708 148.8%  
Other income Rs m2,062897 229.9%   
Total revenues Rs m43,29628,605 151.4%   
Gross profit Rs m8,2916,235 133.0%  
Depreciation Rs m3,8511,027 375.0%   
Interest Rs m6157 8,785.7%   
Profit before tax Rs m5,8876,098 96.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,292 68.5%   
Profit after tax Rs m4,5313,806 119.0%  
Gross profit margin %20.122.5 89.4%  
Effective tax rate %26.737.6 70.9%   
Net profit margin %11.013.7 80.0%  
BALANCE SHEET DATA
Current assets Rs m41,48615,922 260.6%   
Current liabilities Rs m21,4136,235 343.4%   
Net working cap to sales %48.735.0 139.2%  
Current ratio x1.92.6 75.9%  
Inventory Days Days6464 100.5%  
Debtors Days Days9421 451.3%  
Net fixed assets Rs m50,6617,539 672.0%   
Share capital Rs m3,000230 1,304.3%   
"Free" reserves Rs m48,80821,962 222.2%   
Net worth Rs m51,80822,192 233.5%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89729,839 334.8%  
Interest coverage x10.6872.1 1.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.9 44.5%   
Return on assets %5.212.8 40.3%  
Return on equity %8.717.2 51.0%  
Return on capital %9.627.5 35.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0587,587 158.9%   
Fx outflow Rs m7,3487,145 102.8%   
Net fx Rs m4,710442 1,065.6%   
CASH FLOW
From Operations Rs m6,6213,739 177.1%  
From Investments Rs m-6,840-731 935.7%  
From Financial Activity Rs m-2,397-1,972 121.6%  
Net Cashflow Rs m-2,6121,036 -252.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   CADILA HEALTHCARE  SUVEN LIFESCIENCES  CIPLA  WOCKHARDT  VENUS REMEDIES  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips 150 Points; TCS & Yes Bank Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note. Investors turned cautious ahead of global as well as domestic macroeconomic data release.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Dec 10, 2019 01:53 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS